1-5 of 5
Stephan vom Dahl
Close
Sort by
Journal Articles

Determinants of Persisting Thrombocytopenia In Patients with Type 1 Gaucher Disease Treated with Alglucerase/Imiglucerase for 4–5 Years

Maria D. Cappellini, MD, Nadia Belmatoug, Alex Cole, Stephan vom Dahl, Patrick Deegan, Jack Goldblatt, Barry E. Rosenbloom, MD, Anna Tylki-Szymañska, Neal J. Weinreb, MD, Ari Zimran, MD, Carla Hollak, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 4719.
https://doi.org/10.1182/blood.V116.21.4719.4719
Published: 2010
Journal Articles

Long-Term Data From the ICGG Gaucher Registry: Clinical Parameters After 10 Years of Treatment with Imiglucerase.

Neal J. Weinreb, MD, Stephan vom Dahl, MD, Maria Domenica Cappellini
Journal: Blood
Blood (2009) 114 (22): 3590.
https://doi.org/10.1182/blood.V114.22.3590.3590
Published: 2009
Journal Articles

A Report from the International Collaborative Gaucher Group (ICGG) Gaucher Registry

Neal J. Weinreb, MD, Stephan vom Dahl, MD
Journal: Blood
Blood (2008) 112 (11): 3549.
https://doi.org/10.1182/blood.V112.11.3549.3549
Published: 2008
Journal Articles

Low-dose versus high-dose therapy for Gaucher disease: goals and markers

Carla E. M. Hollak, Maaike de Fost, Johannes M. F. G. Aerts, Stephan vom Dahl
Journal: Blood
Blood (2007) 109 (1): 387.
https://doi.org/10.1182/blood-2006-07-033233
Published: 2007
Journal Articles

Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis

Clinical Trials & Observations
Maaike de Fost, Carla E. M. Hollak, Johanna E. M. Groener, Johannes M. F. G. Aerts, Mario Maas, Ludger W. Poll, Maaike G. Wiersma, Dieter Häussinger, Sarah Brett, Nicole Brill, Stephan vom Dahl
Journal: Blood
Blood (2006) 108 (3): 830–835.
https://doi.org/10.1182/blood-2005-12-5072
Published: 2006